Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | FDPS | P14324 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21648859 | 1.00 | MGLL (0.41) | MGLLFAAHFDPSCYP1A2GPR84 | |
| SCHEMBL23901147 | 1.00 | MGLL (0.41) | MGLLFAAHFDPSCYP1A2GPR84 | |
| SCHEMBL21575529 | 1.00 | MGLL (0.41) | MGLLFAAHFDPSCYP1A2GPR84 | |
| SCHEMBL11712575 | 0.91 | FDPS (0.38) | MGLLFAAHFDPSGPR84FFAR1 | |
| SCHEMBL8632296 | 0.84 | MGLL (0.41) | MGLLFAAHFDPSGPR84FFAR1 | |
| SCHEMBL8829436 | 0.84 | MGLL (0.41) | MGLLFAAHFDPSGPR84FFAR1 | |
| SCHEMBL8626067 | 0.84 | MGLL (0.41) | MGLLFAAHFDPSGPR84FFAR1 | |
| SCHEMBL8629338 | 0.84 | MGLL (0.41) | MGLLFAAHFDPSGPR84FFAR1 | |
| SCHEMBL18923684 | 0.83 | CHRM2 (0.34) | MGLLFAAHFDPSKMT2ALMNA | |
| SCHEMBL23921640 | 0.83 | FAAH (0.39) | MGLLFAAHFDPSGPR84ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308277-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308277-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | CD2BP2, DCLRE1A, EPCAM | MGLL 3354/4885FAAH 1559/4885FDPS 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.